Complement in Lupus: Biomarker, Therapeutic Target, or a Little Bit of Both?
作者信息
Cantarelli Chiara, Leventhal Jeremy, Cravedi Paolo
机构信息
UO Nefrologia, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy.
Division of Nephrology, White Plains Hospital, White Plains, New York, USA.
出版信息
Kidney Int Rep. 2021 Jun 26;6(8):2031-2032. doi: 10.1016/j.ekir.2021.06.016. eCollection 2021 Aug.
Abstract
摘要
相似文献
1
Complement in Lupus: Biomarker, Therapeutic Target, or a Little Bit of Both?
Kidney Int Rep. 2021 Jun 26;6(8):2031-2032. doi: 10.1016/j.ekir.2021.06.016. eCollection 2021 Aug.
2
Complement C4d as a biomarker for systemic lupus erythematosus and lupus nephritis.
Lupus. 2024 Feb;33(2):111-120. doi: 10.1177/09612033231226351. Epub 2024 Jan 16.
3
The complement system in pediatric systemic lupus erythematosus, atypical hemolytic uremic syndrome, and complocentric membranoglomerulopathies.
Curr Opin Rheumatol. 2012 Sep;24(5):522-9. doi: 10.1097/BOR.0b013e328356896b.
4
Intertwined pathways of complement activation command the pathogenesis of lupus nephritis.
Transl Res. 2022 Jul;245:18-29. doi: 10.1016/j.trsl.2022.03.005. Epub 2022 Mar 14.
5
Microvascular C5b-9 deposition in non-lesional skin in patients with SLE and its correlation with active lupus nephritis: a prospective observational study.
Lupus Sci Med. 2023 Oct;10(2). doi: 10.1136/lupus-2023-000996.
6
Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology-Classified Systemic Lupus Erythematosus.
Arthritis Rheumatol. 2020 Jan;72(1):78-88. doi: 10.1002/art.41093. Epub 2019 Nov 25.
7
Expanding the Role of Complement Therapies: The Case for Lupus Nephritis.
J Clin Med. 2021 Feb 7;10(4):626. doi: 10.3390/jcm10040626.
8
Coagulation cascade and complement system in systemic lupus erythematosus.
Oncotarget. 2017 Dec 11;9(19):14862-14881. doi: 10.18632/oncotarget.23206. eCollection 2018 Mar 13.
9
Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare.
Clin J Am Soc Nephrol. 2016 Jan 7;11(1):47-53. doi: 10.2215/CJN.03990415. Epub 2015 Dec 23.
10
Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification.
Expert Rev Clin Immunol. 2017 Dec;13(12):1133-1142. doi: 10.1080/1744666X.2017.1392238. Epub 2017 Nov 6.
引用本文的文献
1
Complement Membrane Attack Complexes Disrupt Proteostasis to Function as Intracellular Alarmins.
Res Sq. 2024 Jun 19:rs.3.rs-4504419. doi: 10.21203/rs.3.rs-4504419/v1.
2
Integrative analysis of single-cell and bulk transcriptome data reveal the significant role of macrophages in lupus nephritis.
Arthritis Res Ther. 2024 Apr 12;26(1):84. doi: 10.1186/s13075-024-03311-y.
3
Exploring the Molecular Mechanisms and Shared Gene Signatures Between Systemic Lupus Erythematosus and Bladder Urothelial Carcinoma.
Int J Gen Med. 2024 Feb 28;17:705-723. doi: 10.2147/IJGM.S448720. eCollection 2024.
4
Demethylation of CDKN2A in systemic lupus erythematosus and rheumatoid arthritis: a blood biomarker for diagnosis and assessment of disease activity.
Clin Rheumatol. 2023 Dec;42(12):3387-3395. doi: 10.1007/s10067-023-06736-z. Epub 2023 Aug 19.
5
Pathogenic cellular and molecular mediators in lupus nephritis.
Nat Rev Nephrol. 2023 Aug;19(8):491-508. doi: 10.1038/s41581-023-00722-z. Epub 2023 May 24.
本文引用的文献
1
The Influence of an Elastase-Sensitive Complement C5 Variant on Lupus Nephritis and Its Flare.
Kidney Int Rep. 2021 Jun 9;6(8):2105-2113. doi: 10.1016/j.ekir.2021.05.029. eCollection 2021 Aug.
2
Expanding the Role of Complement Therapies: The Case for Lupus Nephritis.
J Clin Med. 2021 Feb 7;10(4):626. doi: 10.3390/jcm10040626.
3
Loss of decay-accelerating factor triggers podocyte injury and glomerulosclerosis.
J Exp Med. 2020 Sep 7;217(9). doi: 10.1084/jem.20191699.
4
A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy.
BMC Nephrol. 2020 Jun 30;21(1):245. doi: 10.1186/s12882-020-01888-5.
5
New insights into the immunopathogenesis of systemic lupus erythematosus.
Nat Rev Rheumatol. 2016 Nov 22;12(12):716-730. doi: 10.1038/nrrheum.2016.186.
6
Systemic Lupus Erythematosus and Deficiencies of Early Components of the Complement Classical Pathway.
Front Immunol. 2016 Feb 24;7:55. doi: 10.3389/fimmu.2016.00055. eCollection 2016.
7
Functional analysis of a complement polymorphism (rs17611) associated with rheumatoid arthritis.
J Immunol. 2015 Apr 1;194(7):3029-34. doi: 10.4049/jimmunol.1402956. Epub 2015 Feb 27.
8
C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion.
J Immunol. 2007 Feb 1;178(3):1819-28. doi: 10.4049/jimmunol.178.3.1819.
9
Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.
Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8563-8. doi: 10.1073/pnas.93.16.8563.
Zotero 插件